Literature DB >> 26527061

cAMP/PKA enhances interleukin-1β-induced interleukin-6 synthesis through STAT3 in glial cells.

Kumiko Tanabe1, Osamu Kozawa2, Hiroki Iida3.   

Abstract

We previously reported that interleukin (IL)-1β induces IL-6 synthesis via activation of the IκB/NFκB pathway, p38 mitogen-activated protein (MAP) kinase, stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and signal transducer and activator of transcription (STAT)3, but not p44/p42 MAP kinase in rat glioma cell line, C6 cells and that cAMP enhances the IL-6 synthesis. However, the details behind enhancement of IL-1β-induced IL-6 synthesis by cAMP remain to be elucidated. In the present study, we investigated the exact mechanism of cAMP underlying the amplification of IL-1β-induced IL-6 synthesis in C6 cells. 8-Bromo cAMP significantly enhanced IL-1β-induced STAT3 phosphorylation without affecting phosphorylation of IκB, p38 MAP kinase or SAPK/JNK. In addition, we found that forskolin, a direct activator of adenylyl cyclase, significantly enhanced IL-1β-induced STAT3 phosphorylation. Janus family of tyrosine kinase (JAK) inhibitor I markedly suppressed the amplification by 8-bromo cAMP of IL-1β-induced IL-6 release. IL-1β induced JAK2 phosphorylation, and FLLL32, a specific JAK2 inhibitor, significantly reduced IL-1β-stimulated IL-6 release. 4-Cyano-3-methylisoquinoline, an inhibitor of protein kinase A (PKA), significantly attenuated the enhancing effect of 8-bromo cAMP on IL-1β-induced STAT3 phosphorylation. 8-Bromo cAMP markedly induced JAK2 phosphorylation. PKA siRNA transfection reduced enhancement of IL-1β-induced IL-6 release by 8-bromo cAMP. In conclusion, our results strongly suggest that the adenylyl cyclase/cAMP/PKA pathway upregulates IL-1β-induced IL-6 synthesis through enhancement of the JAK2/STAT3 pathway in C6 glioma cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine; Interleukin-1β; Interleukin-6; JAK2; STAT3; cAMP

Mesh:

Substances:

Year:  2015        PMID: 26527061     DOI: 10.1016/j.cellsig.2015.10.009

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

1.  Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Authors:  Syed F Hassnain Waqas; Anh Cuong Hoang; Ya-Tin Lin; Grace Ampem; Hind Azegrouz; Lajos Balogh; Julianna Thuróczy; Jin-Chung Chen; Ivan C Gerling; Sorim Nam; Jong-Seok Lim; Juncal Martinez-Ibañez; José T Real; Stephan Paschke; Raphaëlle Quillet; Safia Ayachi; Frédéric Simonin; E Marion Schneider; Jacqueline A Brinkman; Dudley W Lamming; Christine M Seroogy; Tamás Röszer
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808

2.  p38 Expression and Modulation of STAT3 Signaling in Oral Cancer.

Authors:  I Gkouveris; N Nikitakis; A Sklavounou
Journal:  Pathol Oncol Res       Date:  2018-03-21       Impact factor: 3.201

3.  Remifentanil suppresses increase in interleukin-6 mRNA in the brain by inhibiting cyclic AMP synthesis.

Authors:  Shigeru Maeda; Tsugunobu Andoh; Rieko Onishi; Yumiko Tomoyasu; Hitoshi Higuchi; Takuya Miyawaki
Journal:  J Anesth       Date:  2018-08-30       Impact factor: 2.078

4.  miR-365 targets β-arrestin 2 to reverse morphine tolerance in rats.

Authors:  Jian Wang; Wei Xu; Tao Zhong; Zongbin Song; Yu Zou; Zhuofeng Ding; Qulian Guo; Xinzhong Dong; Wangyuan Zou
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

5.  The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.

Authors:  Carlo Cenciarelli; Hany E Marei; Manuela Zonfrillo; Patrizia Casalbore; Armando Felsani; Stefano Giannetti; Gianluca Trevisi; Asma Althani; Annunziato Mangiola
Journal:  Oncotarget       Date:  2017-03-14

6.  Discovery of BVDU as a promising Drug for autoimmune diseases Therapy by Dendritic-cell-based functional screening.

Authors:  Shuai Chen; Jinfeng Zhou; Yingying Cai; Xinyuan Zheng; Sirong Xie; Yuhan Liao; Yu Zhu; Chaoyan Qin; Weiming Lai; Cuixia Yang; Xin Xie; Changsheng Du
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

Review 7.  Purinergic Signaling in the Regulation of Gout Flare and Resolution.

Authors:  Xiaoling Li; Jie Gao; Jinhui Tao
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

Review 8.  Multifaceted Roles of cAMP Signaling in the Repair Process of Spinal Cord Injury and Related Combination Treatments.

Authors:  Gang Zhou; Zhiyan Wang; Shiyuan Han; Xiaokun Chen; Zhimin Li; Xianghui Hu; Yongning Li; Jun Gao
Journal:  Front Mol Neurosci       Date:  2022-02-23       Impact factor: 5.639

Review 9.  The Current Role of Dexmedetomidine as Neuroprotective Agent: An Updated Review.

Authors:  Zaara Liaquat; Xiaoying Xu; Prince Last Mudenda Zilundu; Rao Fu; Lihua Zhou
Journal:  Brain Sci       Date:  2021-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.